Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective
of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the
treatment of relapsed or refractory NHL,respectively.